The prevalence of type-2 diabetes is increasing at
|
|
- Suzanna Jemima Holmes
- 5 years ago
- Views:
Transcription
1 Non-insulin injectable therapy The prevalence of type-2 diabetes is rapidly increasing with up to a quarter of people over 60 years of age affected it. To reduce the risk of the associated microvascular and macrovascular complications, national guidelines for glycaemic control recommend HbA1c targets of between %. In recent years two novel GLP 1 receptor agonists exenatide and liraglutide have become available for clinical use. These drugs work via the incretin system and are licensed for the treatment of people with type-2 diabetes. These agents are administered as a fixed dose subcutaneous injection. The use of these agents is supported NICE guidelines as an alternative to insulin treatment in persons who have HbA1c levels of greater than 7.5% and a BMI greater than 35. Dr Vinay Eligar Department of Diabetes, Singleton hospital, Sketty Lane, Swansea Dr Richard Chudleigh Department of Diabetes, Singleton hospital, Sketty Lane, Swansea * Richard.Chudleigh3@wales.nhs.uk The prevalence of type-2 diabetes is increasing at an alarming rate. 1 Current estimates suggest that 2030 the worldwide prevalence will be 366 million. It is the older age group who are especially at risk of type-2 diabetes. In Europe and the US the prevalence of diabetes in patients over 60 years of age is between 15% and 23%. 2,3 Type-2 diabetes with its associated complications causes significant morbidity and mortality. Patients are at risk of both microvascular and macrovascular complications. Elderly patients newly diagnosed with type-2 diabetes have especially high rates of these complications. 4 Currently, agencies such as NICE 5 and the American Diabetes Association (ADA) 6 set HbA1c targets of between 6.5% and 7.5%. The ADA has suggested HbA1c of less than 7.0% as a target for glycaemic control. The UK Prospective Diabetes Study (UKPDS) 7 showed a in microvascular complications in subjects treated with intensive glycaemic control from diagnosis of type-2 diabetes. The Steno-2 study of patients with type-2 diabetes and microalbumnuria demonstrated a 50% in cardiovascular and microvascular complications with intensive multifactorial intervention over 7.8 years. 8 The achievement of target HbA1c depends on adherence to dietary and lifestyle measures as well as pharmacological interventions. In the elderly patient this pharmacological therapy must also be individualised to account for comorbidity, long-term prognosis and social factors. Pharmacotherapy has traditionally ranged from insulin sensitisers (metformin and thiazolidinediones) or insulin secretogogues (sulphonylureas) to insulin, with insulin being reserved for those not meeting targets with oral agents. Although insulin is effective in achieving glycaemic control there are associated risks of hypoglycaemia and also weight gain. In elderly patients limiting the adverse consequences of hypoglycaemia is an important consideration. There can also be reluctance to use treatment that causes weight gain in this group. The recent availability of incretin hormones has given healthcare professionals an alternative choice to insulin therapy and is likely to revolutionise the pharmacological management of type-2 diabetes. Currently, exenatide (Byetta) and liraglutide (Victoza) are the only synthetic analogues of glucagon like polypeptide-1 (GLP-1) available. These agents are injectable and come as a fixed dose preparation, which are slowly titrated. Exenatide is administered twice daily while liraglutide is a once-daily treatment. These agents have been shown to improve glycaemic control and promote weight loss. Pharmacology/method of action The incretin hormones are released from gastrointestinal L and K cells, in response to the ingestion of food. They stimulate glucose dependent insulin release from β-cells and inhibit glucagon release. 9 Circulating levels increase rapidly in the postprandial period and exert their main effect delayed gastric emptying, slower nutrient absorption and early satiety. These effects all promote weight loss. Glucagon-Like Polypeptide-1 (GLP-1) and Gastric Inhibitory Peptide (GIP) are the two molecules recognised to have incretin effect. Endogenous GLP- GM2 Midlife and Beyond 2011 April 11
2 Table 1: Pivotal exenatide studies Study Number and antidiabetic agents Duration and exenatide dose Comparator drug Hba1c exenatide Hba1c comparator weight exenatide weight comparator drug Hypoglycaemia exenatide vs. comparator drug De Fronzo et al MET 30 wks 5 or 10 µg BID SC Placebo -0.4% to -0.78% +0.8% -1.6 kg to -2.8 kg -0.3 kg 5% vs 5% Kendall et al MET+SU 30 wks 5 or 10 µg BID SC Placebo -0.6% to -0.8% +0.2% -1.6 kg -0.9 kg 23% vs 13% Zinmann et al TZD±MET 16 wks 10 µg BID SC Placebo -0.89% +0.09% kg kg 11% vs 7% 1 displays a very short circulating half-life of two minutes due to rapid renal clearance and NH2-terminal degradation the enzyme Dipeptidyl peptidase-4 (DPP-4). The synthetic analogues of GLP-1 or Glucagon-Like Polypeptide-1 Receptor agonists (GLP- 1R agonists) are resistant to DPP-4 enzyme breakdown and prolong stimulation of the β-cell. 10 Exogenous GLP-1R agonists administration can enhance insulin secretion and lower plasma glucose effectively. 11,12 Due to their mode of action the most commonly encountered adverse effect of these agents are nausea and vomiting occurring in up to 23% of patients. This is often transient and dose dependent. Other adverse effects include mild hypoglycaemia, dyspepsia, diarrhoea, constipation, malaise and generalised oedema. 13 Hypoglycaemia was more commonly noted when prescribed in association with sulphonylurea therapy 14 hence in dose of these agents is recommended when co-prescribed with GLP-1 receptor agonists. More serious adverse events such as pancreatitis and renal failure have been reported. However, a review of 30 cases of pancreatitis reported in patients on exenatide showed that 90% had other factors that could predispose to pancreatitis. 15 In the cases of renal failure reported 16 often other factors such as plasma volume contraction secondary to nausea and vomiting or reduced fluid intake were contributing to the problem. There is no evidence that exenatide is directly nephrotoxic. Supportive therapy, stopping nephrotoxic drugs, including exenatide should reverse renal failure. 17 Clinical evidence Exenatide Exenatide was the first GLP-1R agonist released to the market. It was introduced in the US in 2005 and Europe in Clinical studies have demonstrated glucose-lowering effect with s in HbA1c and significantly less hypoglycaemia. 18,19,20 Significant weight loss has also been demonstrated. The twice daily dosing of exenatide resulted in a mean in HbA1c of 1.5% after 30 weeks. 18,19 Larger s have been reported with once weekly formulation, which is not yet licensed for clinical use. 21,22 weight loss of -3.6 kg 30 weeks and -5.3 kg at 3.5 years was evident in pivotal clinical trials. 23 Much larger s were noted in individual patients, whose baseline HbA1c and weight was much higher. Patients on exenatide treatment also reported fewer episodes of hypoglycaemia (up to 17%), when compared with patients treated with insulin glargine or aspart. Hypoglycaemic events were lower in patients treated with metformin as adjuvant therapy compared with patients on insulin or sulphonylureas. Apart from above desired effects, exenatide has also shown improvements in cardiovascular risk factors 12
3 Table 2: Pivotal liraglutide studies Trial (duration) Liraglutide+ drug Drugs compared Number of subjects HbA1c % change Weight (kg) change LEAD-1 (26 weeks Liraglutide+glimepiride Rosiglitazone 4 mg placebo LEAD-2 Liraglutide+metformin 27 Glimepiride 4 mg placebo LEAD-3 (52 weeks) Liraglutide only 28 Glimepiride 8 mg LEAD-4 Liraglutide+metformin +rosiglitazone 29 Placebo LEAD-5 Liraglutide+metformin +glimepiride 30 Glargine placebo LEAD-6 Liraglutide+metformin ±sulphonylurea 31 Exenatide 10μg , 24 such as, blood pressure and lipid profile. Exenatide is administered twice daily as a subcutaneous (SC) injection in dose of 5 or 10 μg within one hour before the two major meals of the day, which should be eaten at least six hours apart. Initial dose is 5 μg twice a day for one month and increased to 10 μg if nausea is not a limiting factor. The drug is delivered via pen device, which delivers 60 fixed doses, so each pen lasts for one month. Exenatide is not used in type-1 diabetes and is contraindicated in renal impairment. Liraglutide Liraglutide is the first acylated analogue of human GLP-1 and shares 97% sequence homology to native GLP It was licensed in Europe in July 2009 and introduced to the US and Japan in January It is highly protein bound that makes it long acting with a half life of 13 hours and hence is used conveniently as a once daily preparation. The clinical effects of liraglutide have been investigated in the LEAD (Liraglutide Effect and Action in Diabetes) series of phase III studies, which included over 4000 patients with type-2 diabetes Liraglutide demonstrated effective of HbA1c and weight when used alone and in combination with other available oral agents. The net were similar at 1.2 mg and 1.8 mg dose, hence NICE guidelines have not recommended the highest dose. It is started at 0.6 mg SC OD for initial one month and increased to 1.2 mg SC OD. It is delivered via pen device with fixed dose. It is licensed for use as combination either with metformin and sulphonylurea or thiazolidinediones as part of a triple therapy regime. The LEAD 6 trial demonstrated that liraglutide produced a greater in HbA1c when compared to exenatide. Liraglutide achieved greater s in fasting blood glucose, however exenatide had better glucose lowering effect in the post-prandial period. 14
4 There was no significant difference in the degree of weight loss observed. 31 Combination treatment with insulin Currently GLP-1R agonists are not licensed for use in combination with insulin. However, some specialists have used this off license combination in specific circumstances and have reported encouraging early results. The addition of exenatide to insulin-based therapy has been reported to produce s in HbA1c, weight, and prandial insulin requirements. 13 A study presented at the European Association for the Study of Diabetes in September 2010, compared the combination of exenatide and insulin glargine with a group treated with a placebo and insulin glargine group. The exenatide group had a greater improvement HbA1c level and modest weight loss with no increase in hypoglycaemia. 32 Once weekly formulations Currently there are several novel agents with a longer half life under evaluation in clinical trials. These include once weekly exenatide (Exenatide QW), Taspoglutide, Albiglutide and AVE These agents have shown improvements in glycaemic control and have promoted weight loss. Exenatide QW, has shown improved glycaemic control compared to twice-daily exenatide with a lower incidence of adverse-effects. 37 Clinical trials have demonstrated improvement in cardiovascular risk factors with s in systolic blood pressure and improved lipid parameters. It also preserves β-cell mass and function probably due to sustained stimulation. FDA is awaiting thorough QT study data before deciding on approval. Arrival of these newer agents will widen the choice of GLP-1 analogues available. Clinical guidelines NICE guidelines NICE guidance 5,37 which following a recent update are applicable to exenatide and liraglutide, state xx
5 that GLP-1 receptor agonists can be considered as part of a triple therapy regime in combination with metformin and sulphonylurea or metformin and thiazolidinedione if blood glucose control is inadequate with HbA1c >7.5% if the following criteria are met. Body mass index (BMI) 35 kg/m 2 and specific psychological or medical problems associated with high body weight, or BMI <35 kg/m 2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity related comorbidities. The guideline also states that The GLP-1R agonists are to be continued only if HbA1c drops 1% and body weight reduces 3% after six months. Conclusion The GLP 1 receptor agonists provide an important new therapeutic option for use in the obese patient with type-2 diabetes. They provide an alternative option to insulin treatment, especially when further weight gain is a concern. The major advantages are reduced risks of hypoglycaemia, fixed dose regimes and easy to use pen devices. Studies thus far have included patients between the ages of 18 and 76 years. No studies have specifically addressed the elderly age group. Caution should be exercised in those with evidence of renal impairment or gastrointestinal problems. Conflict of interest: none declared References 1. Zimmer P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414: Cowie CC, Rust KF; Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in and Diabetes Care 2009; 32(2): Report: Prevalence of diabetes in western board area, Northern Ireland. Brendan Bonner, Investing for Health Partnership, August Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med 2007; 167 (9): National Institute for Health and Clinical Excellence. Type 2 diabetes; the management of type 2 diabetes, NICE clinical guideline 87. London: NICE, www. nice.org.uk Accessed 12/04/11 6. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009; 32(1): S13 S61 7. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with mac- rovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: Gæde P, Vedel P, Larsen N, et al. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003; 348: Kjems LL. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on B-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: Drucker DJ, Sherman SI, Gorelick FS, et al. Incretinbased therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33(2): Nauck MA. Preserved incretin activity of glucagonlike peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91: Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: Nancy M. Yoon, Melissa K. Cavaghan, Rocco L. Brunelle, Paris Roach. Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting: Clinical Therapeutics 2009; 31(7): Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26(3): Ahmad SR, Swann J. Exenatide and rare adverse events. NEJM 2008; 358: Weise WJ, Sivanandy MS, et al. Exenatide-Associated Ischemic Renal Failure; Diabetes care 2009; 32(2) 17. Amylin Pharmaceuticals, Inc. GM2 Midlife and Beyond 2011 April 17
6 com. Accessed 12/04/ DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: Kim D, MacConell L, Zhuang D, et al. Effects of onceweekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type2 diabetes. Diabetes Care 2007; 30: Drucker DJ, Buse JB, Taylor K, et al; for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferi- ority study. Lancet 2008; 372: Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo controlled, parallel-group study. Clin Ther 2008; 30: Knudsen LB et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: Nauck MA, Frid A, Hermansen K, et al; for the LEAD-2 Metformin Study Group. Efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes mellitus. Diabetes Care 2009; 32: Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD- 3 Mono): a randomised, 52- week, phase III, doubleblind, parallel-treatment trial. Lancet 2009;373: Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met +TZD). Diabetes Care 2009;32: Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomized controlled trial. Diabetologia 2009;52: Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 2009; 374: Exenatide Plus Insulin Glargine Provides Excellent Glucose Control Without Hypoglycemia in Type 2 Diabetes; Daniel M. Keller: European Association for the Study of Diabetes 46th Annual Meeting. 33. Werner U. Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. Annales d Endocrinologie 2008; 69: Rosenstock J. Reusch J. Bush M. Yang F. Stewart M. Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009; 32: Nauck MA. Ratner RE. Kapitza C. Berria R. Boldrin M. Balena R. Treatment with the human onceweekly glucagon-like peptide-1analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo controlled study. Diabetes Care 2009; 32: Kim D. Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes. Diabetes Care 2007; 30: National Institute of Health and Clinical Excellence. Liraglutide for the treatment of type 2 diabetes mellitus. NICE technology appraisal guidance 203. London: NICE, October Accessed 12/04/11 18
Scottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationLiraglutide: First Once-Daily Human GLP-1 Analogue
DRUG PROFILE KERALA MEDICAL JOURNAL Liraglutide: First Once-Daily Human GLP-1 Analogue Sreejith N Kumar Research Cell, IMA Kerala State, K-5, Kochar Road, Sasthamangalam Thiruvananthapuram* ABSTRACT Published
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationthe person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and
Exenatide (Byetta) and Liraglutide (Victoza) prescribing guidance: Notes for initiation in primary care These incretin mimetics are given by subcutaneous injection once or twice daily. They have similar
More informationGLP-1 Agonists for Diabetes
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSYSTEMATIC REVIEW. Introduction. X. Xue, 1 Z. Ren, 1 A. Zhang, 2 Q. Yang, 3 W. Zhang, 4 F. Liu 1,4
SYSTEMATIC REVIEW Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationGlucagon-Like Peptide-1 (GLP-1) Agonists
Glucagon-Like Peptide-1 (GLP-1) Agonists Policy Number: 5.01.565 Last Review: 07/2018 Origination: 06/2014 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 December 2009 VICTOZA 6 mg/ml solution for injection in pre-filled pen Pack size of two 3 ml pens (CIP: 396 323-6)
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationExpanding Treatment Options for Diabetes: GLP-1 Receptor Agonists. Copyright
CLINICAL Viewpoint Expanding Treatment Options for Diabetes: GLP-1 Receptor Agonists Advancements in Diabetes Management: A Canadian Diabetes Steering Committee Report Copyright Not for Sale or Commercial
More informationSelecting GLP-1 RA Treatment
Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationIncretin-Based therapy for type 2 diabetes: overcoming unmet needs
2 : 15 Incretin-Based therapy for type 2 diabetes: overcoming unmet needs Diabetes is a progressive disease characterised by impaired betacell function, and reduced insulin sensitivity and secretion. Over
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationDiabetes Management Incretin Mimetics
The Incretin System and Type 2 Diabetes Anthony H Barnett, MD Professor of Medicine, Consultant Physician, and Clinical Director of Diabetes and Endocrinology, University of Birmingham and Heart of England
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationGlucagon-like peptide-1 (GLP-1) is an
THE NEW SCIENCE OF GLP-1: EFFECTS BEYOND GLUCOSE CONTROL Richard E. Pratley, MD ABSTRACT The incretin hormone, glucagon-like peptide- 1 (GLP-1) has well-characterized effects on glucose homeostasis that
More informationRESEARCH. What this study adds. What is already known about this subject
RESEARCH Evaluating the Short-Term Cost-Effectiveness of Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States Jakob Langer, MSc; Barnaby Hunt, BSc; and
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationDrug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists
Texas Vendor Drug Program Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists Publication History Developed February 2006. Revised September 2018; September 2016; June 2015; October 2013; December
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationINJECTABLE THERAPIES IN DIABETES. Barbara Ann McKee Diabetes Specialist Nurse
INJECTABLE THERAPIES IN DIABETES Barbara Ann McKee Diabetes Specialist Nurse 1 Aims of the session Describe the different injectable agents for diabetes and when they would be used. Describe some common
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationEfficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Supplement issue Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD Diabetes and Metabolism Translational Medicine
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More information(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2
007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase
More informationIt is estimated that approximately 20.8 million Americans
FORMULARY MANAGEMENT Managed Care Perspective on Three New Agents for Type 2 Diabetes Shawna VanDeKoppel, PharmD; Hae Mi Choe, PharmD, CDE; and Burgunda V. Sweet, PharmD, FASHP ABSTRACT BACKGROUND: Despite
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationTargeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Richard E. Pratley and Matthew Gilbert
REVIEW Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors Richard E. Pratley and Matthew Gilbert Diabetes and Metabolism Translational Medicine Unit, University
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationCurrent Status of Incretin Based Therapies in Type 2 Diabetes
Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationSELECTED ABSTRACTS AND POSTER PRESENTATIONS
SELECTED ABSTRACTS AND POSTER PRESENTATIONS The following summaries are based on abstracts and posters presented at the American Diabetes Association s 65th Annual Scientific Sessions held in San Diego,
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationLiraglutide (Victoza)
Liraglutide (Victoza) The First Once-Daily Incretin Mimetic Injection For Type-2 Diabetes Sylvia H. Jackson, PharmD, CDE, MEd; Tonya S. Martin, PharmD, CGP, MAEd; Jocelyn D. Jones, PharmD, BCPS; David
More informationUpdate on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American
Update on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American Association of Diabetes Educators (AADE) for nurses, dietitians,
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationAlbiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationBy Eulalia Barajas-Graham
Clinical Review of Incretin Based Therapies: Their Role in the Management of Type 2 Diabetes Mellitus. By Eulalia Barajas-Graham A Capstone Paper submitted to the faculty of the University of North Carolina
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationPresented By: Creative Educational Concepts, Inc. Lexington, KY
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 2015. The content and views presented in this educational activity are those of the
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More information